Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies
- 1 June 2022
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 79 (6) , 525-527
Abstract
This Viewpoint discusses the risk-benefit assessments in psychedelic and 3,4-methylenedioxymethamphetamine (MDMA)–assisted therapies.Keywords
This publication has 7 references indexed in Scilit:
- Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic researchPsychopharmacology, 2022
- Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studiesJournal of Affective Disorders Reports, 2021
- RETRACTED ARTICLE: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trialsPsychopharmacology, 2020
- The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot studyJournal of Psychopharmacology, 2010
- Human hallucinogen research: guidelines for safetyJournal of Psychopharmacology, 2008
- ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATUREJournal of Nervous & Mental Disease, 1984
- Prolonged Adverse Reactions to Lysergic Acid DiethylamideArchives of General Psychiatry, 1963